PGEN · PRECIGEN, INC.

Precigen Inc Is A Commercial-Stage Biopharmaceutical Company Focused On Developing Precision Medicines To Improve The Lives Of Patients, Targeting Immuno-Oncology, Autoimmune Disorders, And Infectious Diseases Using Its Proprietary And Complementary Technology Platforms. These Platforms Support The Development Of Gene Programs, Delivery Through Viral, Non-Viral, And Microbe-Based Approaches, And Control Of Gene Expression For Safety And Efficacy. Its Key Platforms Include Adenoverse Immunotherapy And Ultracar-T, Supported By The Ultraporator Device For Rapid And Cost-Effective Manufacturing. Its Clinical Pipeline Includes Prgn-2009, Prgn-3005, Prgn-3006, And Prgn-3007. Its Reportable Segments Are Biopharmaceuticals And Exemplar.